AMRI wins BioSpectrum-BioSingapore Special Award 2011

Published: 18-Mar-2011
Research & Development Pharmaceutical

Inaugural winner honored for contributions to the creation of employment opportunities in the life sciences segment in Singapore


AMRI is the inaugural winner of the BioSpectrum-BioSingapore Special Award 2011. AMRI was honored for its contributions to the creation of employment opportunities in the life sciences segment in Singapore .

AMRI established its first research centre in Singapore in 2005. Growing from four to 20 employees in its first year, AMRI's research facilities now employ more than 130 individuals dedicated to delivering biology and chemistry services to customers in the biopharmaceutical industry.

The company's business in Singapore continues to undergo facility expansion and hiring, and anticipates being twice its current size by 2013 in an effort to keep up with continued strong demand for services from its customers.

‘We are very pleased to receive this award,’ said Raymond Yeung, managing director for AMRI's site in Singapore. ‘One of the challenges and successes in growing a research and development business in Singapore has been the ability to source enough scientific talent.

‘It has been a pleasure to work with the Singapore's Economic Development Board and local universities to foster the growth of a talented pool of employees to support our continuing expansion.’

  • Companies:
  • Curia
See more

You may also like

Research & Development

Curia expands biologics capabilities with access to Touchlight’s doggybone DNA

Read more
Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA)

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  3. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  4. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  5. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Curia expands biologics capabilities with access to Touchlight’s doggybone DNA

Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA)
Drug Delivery

Curia and MilliporeSigma sign deal for use of cell line for proteins and antibodies

Following this agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers
Manufacturing

Curia reveals continuous-flow collaboration with Corning

Continuous flow chemistry is critical for the development and manufacture of pharmaceutical intermediates and APIs
Research & Development

AMRI manufactures lipid excipients for Pfizer-BioNTech COVID-19 vaccine

AMRI has been providing development, scale-up and manufacturing services at a number of its global R&D and production sites for several months
Manufacturing

ViralClear partners with CDMO on potential COVID-19 treatment Merimepodib

ViralClear Pharmaceuticals has partnered with Albany Molecular Research Inc (AMRI) on the manufacture of Merimepodib API either as a stand-alone treatment or in combination with other antiviral agents or immune modulator
Manufacturing

AMRI to acquire Euticals

Strategic transaction expands API development and manufacturing business
Research & Development

AMRI and NYCNMR form collaborative agreement

Collaboration to enhance application of nanotechnology in integrated drug discovery setting
Subscribe now